Difference between revisions of "Essential thrombocythemia"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 30: Line 30:
 
# Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. [http://bloodjournal.hematologylibrary.org/content/121/10/1720.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23315161 PubMed]
 
# Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. [http://bloodjournal.hematologylibrary.org/content/121/10/1720.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23315161 PubMed]
  
−
==Hydroxyurea (Hydrea) {{#subobject:762af3|Regimen=1}}==
+
==Aspirin & Hydroxyurea {{#subobject:762af3|Regimen=1}}==
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
Line 46: Line 46:
 
===References===
 
===References===
 
# Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. [http://www.nejm.org/doi/full/10.1056/NEJMoa043800#t=article link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16000354 PubMed]
 
# Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. [http://www.nejm.org/doi/full/10.1056/NEJMoa043800#t=article link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16000354 PubMed]
−
# Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. [http://bloodjournal.hematologylibrary.org/content/121/10/1720.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23315161 PubMed]
+
# Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. Epub 2013 Jan 11. [http://bloodjournal.hematologylibrary.org/content/121/10/1720.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23315161 PubMed]
 +
 
 +
==Hydroxyurea (Hydrea) {{#subobject:762af4|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
 
 +
===Regimen {{#subobject:d87ecd|Variant=1}}===
 +
{| border="1" style="text-align:center;" !align="left"
 +
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|'''Comparator'''
 +
|-
 +
|[http://www.nejm.org/doi/full/10.1056/NEJM199504273321704 Cortelazzo et al. 1995]
 +
|<span
 +
style="background:#00CD00;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Phase III</span>
 +
|[[Essential_thrombocythemia#Observation|Observation]]
 +
|-
 +
|}
 +
 
 +
*[[Hydroxyurea (Hydrea)]] 15 mg/kg/day PO
 +
**Doses were subsequently adjusted to maintain the platelet count at less than 600,000 per cubic millimeter without lowering the white-cell count below 4000 per cubic millimeter
 +
 
 +
===References===
 +
# Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27;332(17):1132-6. [http://www.nejm.org/doi/full/10.1056/NEJM199504273321704 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/7700286 PubMed]
 +
 
 +
==Observation {{#subobject:762af5|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
 
 +
===Regimen {{#subobject:d87ece|Variant=1}}===
 +
{| border="1" style="text-align:center;" !align="left"
 +
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|'''Comparator'''
 +
|-
 +
|[http://www.nejm.org/doi/full/10.1056/NEJM199504273321704 Cortelazzo et al. 1995]
 +
|<span
 +
style="background:#00CD00;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Phase III</span>
 +
|[[Essential_thrombocythemia#Hydroxyurea_.28Hydrea.29|Hydroxyurea]]
 +
|-
 +
|}
 +
 
 +
''No active treatment; used as a comparator arm.''
 +
 
 +
===References===
 +
# Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27;332(17):1132-6. [http://www.nejm.org/doi/full/10.1056/NEJM199504273321704 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/7700286 PubMed]
  
 
[[Category:Chemotherapy regimens]]
 
[[Category:Chemotherapy regimens]]
 
[[Category:Malignant hematology regimens]]
 
[[Category:Malignant hematology regimens]]
 
[[Category:Myeloproliferative neoplasm regimens]]
 
[[Category:Myeloproliferative neoplasm regimens]]

Revision as of 18:42, 22 May 2015

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

8 regimens on this page
9 variants on this page


Untreated

Anagrelide (Agrylin)

back to top

Regimen #1, Harrison et al. 2005

  • Anagrelide (Agrylin) 0.5 mg PO twice daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.")
  • Aspirin 75 mg (100 mg in Australia) PO once daily

Regimen #2, Gisslinger et al. 2013 (ANAHYDRET)

  • Anagrelide (Agrylin) 0.5 mg PO twice daily ("increased until maintenance of the platelet count at normal (=450 x 109/L) or close to normal levels (>450 x 109/L to 600 x 109/L)")
  • Neither aspirin nor Clopidogrel (Plavix) were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion

References

  1. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. link to original article contains verified protocol PubMed content property of HemOnc.org
  2. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. link to original article contains verified protocol PubMed

Aspirin & Hydroxyurea

back to top

Regimen #1, Harrison et al. 2005

  • Hydroxyurea (Hydrea) 500-1000 mg PO once daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.")
  • Aspirin 75 mg (100 mg in Australia) PO once daily

Regimen #2, Gisslinger et al. 2013 (ANAHYDRET)

  • Hydroxyurea (Hydrea) 1500 mg PO once daily ("increased until maintenance of the platelet count at normal (=450 x 109/L) or close to normal levels (>450 x 109/L to 600 x 109/L)")
  • Neither aspirin nor Clopidogrel (Plavix) were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion

References

  1. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. link to original article contains verified protocol PubMed
  2. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. Epub 2013 Jan 11. link to original article contains verified protocol PubMed

Hydroxyurea (Hydrea)

back to top

Regimen

Study Evidence Comparator
Cortelazzo et al. 1995 Phase III Observation
  • Hydroxyurea (Hydrea) 15 mg/kg/day PO
    • Doses were subsequently adjusted to maintain the platelet count at less than 600,000 per cubic millimeter without lowering the white-cell count below 4000 per cubic millimeter

References

  1. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27;332(17):1132-6. link to original article contains verified protocol PubMed

Observation

back to top

Regimen

Study Evidence Comparator
Cortelazzo et al. 1995 Phase III Hydroxyurea

No active treatment; used as a comparator arm.

References

  1. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27;332(17):1132-6. link to original article contains verified protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Essential_thrombocythemia&oldid=7977"